Jefferies Reiterates Buy Rating on Biogen (BIIB) following FDA approval of HD Spinraza for SMA
Tweet Send to a Friend
Jefferies analyst Andrew Tsai reiterated a Buy rating and $210.00 price target on Biogen (NASDAQ: BIIB)The analyst commented, "As we ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
